Pre-made Farletuzumab benchmark antibody ( Whole mAb, anti-FOLR1 therapeutic antibody, Anti-FBP/FOLR/FRalpha/NCFTD Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Farletuzumab biosimilar, Whole mAb, Anti-FOLR1 Antibody: Anti-FBP/FOLR/FRalpha/NCFTD therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Farletuzumab (MORAb-003) is a humanized monoclonal antibody[1] of IgG1/κ which is being investigated for the treatment of ovarian cancer.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-205-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Farletuzumab biosimilar, Whole mAb, Anti-FOLR1 Antibody: Anti-FBP/FOLR/FRalpha/NCFTD therapeutic antibody
INN Name	Farletuzumab
Target	FOLR1
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-III
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2008
Year Recommended	2009
Companies	Ludwig Institute for Cancer Research;Morphotek;Eisai Co Ltd
Conditions Approved	na
Conditions Active	Ovarian cancer;Non-small cell lung cancer
Conditions Discontinued	Solid tumours
Development Tech	na